LLY shown on a daily chart has doubled in the past year with the introduction of new FDA approved drugs into the market. It has but out a series of favorable earnings reports with optimistic realistic guidance and glowing analysts' forecasts. It has done so without any volume pumps and just keeps grinding higher. This is because it is in the shadows of big...
Analyzing the options chain and the chart patterns of AZN AstraZeneca PLC prior to the earnings report this week, I would consider purchasing the 66usd strike price in the money Puts with an expiration date of 2023-11-10, for a premium of approximately $2.30. If these options prove to be profitable prior to the earnings release, I would sell at least half of...
My analysis is on the 2H. I am uniquely qualified in my fundamental analysis. This is a one day until earnings. My thesis is the earnings will stimulate what will be a breakout from a flat bottom triangle. I will buy one share of stock. I will spend a similar amount on call options striking $460 expiring August 11th. I see LLY as surging while PFE is a bit...
PFE just raised its dividend On the chart it has been trending downward as shown also by a down sloping anchored VWAP bands. Price is currently sitting at long term support and two standard deviations below VWAP. It appears to be ready to reverse from the deep undervalued area. In confirmation, teh voume indicator shows moderate increased...
Pfizer may provide a great risk to reward setup. Multi factor trade setup on pfizer likely sees a technical bounce. Keep in mind markets are weak.
AstraZeneca marginally eclipsed its prior cycle highs through the 72.00 level before pulling back to suggest a potential weekly double top pattern, however, I would highlight the lack of momentum divergence at this point, which suggests to me that the current retreat is corrective. On the four-hour time frame, we can clearly see an interim 5-wave sequence has been...
$AZN on 1HR Gap FIll Needed However it is in a downtrend right now. I am expecting a pullback. But Be careful of news catalysts. Potential pump off of that. What are your thoughts. Thanks, Kelly
AZN: The trend is still bullish in the long term but for the short term (1H) has a correction. Observe the money management . Follow, like, or request symbol analysis.
Company completly expensive by multiples EV/EBIT - P/E and revenues will fall so do EPS. In my opinion must drop 40% next three months
AZN on this Monthly timeframe is extremely bullish More interestingly though is the inverted H&S patterns that have formed a long this 50MA line I have counted three in this post, all leading to a bullish result More of a creative post
AZN High-risk Initial Long . SL and TP on the chart. If CFD 10-20x leverage. Move SL on TP.
Hi dudes AZN reaches Good Demand Zone we Suggest Long it in BlackBox Sl:Below Black Box
Immediate targets 55, 53 and 50. Invalidation at 65. Invalidation at 70. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore...
Aridis Pharmaceuticals announced first Investor call of 2022 for today, after the closing bell. Exiting pipeline with 2 phase 3 drugs and their monoclonal antibody cocktail. AstraZeneca PLC (AZN) has a stake in this company. CEO has co-developed several drug which have been sold to Astra Zeneca, Megabits and MedImmune. Aridis Pharmaceuticals can be a potential...
Q: What has the highest probability of occurring? After being one of the strongest performers in 2020 during the initial UK lockdown the stock lost over 30% of its value. In 2021 it has staged a modest recovery but is still over 15% below its all time high requiring an over 20% rally. There is well tested support at 8100p and resistance at 8775p. There is 2...
Big pharma working with Pieris Pharmaceuticals, Inc. (PIRS): AZN AstraZeneca 70Mil upfront payment and 5.4Bil potential milestone payments Boston Pharmaceuticals 10Mil upfront payment and 353Mil potential milestone payments Genentech member of RHHBY Roche Group 20Mil upfront payment and 1.4Bil potential milestone payments SGEN Seagen 35Mil upfront payment and...
PIRS Pieris Pharmaceuticals has collaboration agreements with AstraZeneca, Boston Pharmaceuticals, Servier, Seagen and Genentech, part of Roche. AZN AstraZeneca 70Mil upfront payment and 5.4Bil potential milestone payments Boston Pharmaceuticals 10Mil upfront payment and 353Mil potential milestone payments Genentech member of RHHBY Roche Group 20Mil upfront...
TICKER CODE: AZN Company Name: ASTRAZENECA PLC Industry: US Stocks Health Technology Pharmaceuticals: Major Position Proposed: BUY FOMO ENTRY: 56.00-57.00 ENTRY: (NOT READY) 54.45 - 57.55 1st Partial Take Profit at: 68.60 (End 2021) Stop Loss: 52.00 Technical Analysis: 1) Rising Wedge (Existing Analysis; TP @ 68.62) 2) Inverse Head and Shoulders (Forming 2nd...